Clinical Trials Logo

Clinical Trial Summary

Using a randomized controlled design, standard treatment of group cognitive-behavioral therapy (CBT) according to the Hesslinger protocol is compared to a newly developed group treatment specifically designed for adult patients with ADHD inattentive presentation (ADHD-I) called CBT for ADHD-I (CADDI). Research setting is psychiatric outpatient clinics. Research hypotheses include: 1. The CADDI protocol is more effective than standard treatment in terms of behavioral activation, procrastination, depressive symptoms, functional impairment, and quality of life, 2. Is equally effective in terms of ADHD symptoms, 3. Is more appreciated and tolerable, and 4. Outcome is mediated by mindful awareness. Effects are followed up at 6 and 12 months post treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • ADHD Predominantly Inattentive Type
  • Attention Deficit Disorder with Hyperactivity

NCT number NCT04090983
Study type Interventional
Source Karolinska Institutet
Contact
Status Active, not recruiting
Phase N/A
Start date September 1, 2019
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT03190902 - Cognitive Impairment in Pediatric Onset Multiple Sclerosis N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT01554046 - The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT05452954 - Psychosocial ADHD Interventions - Brief Parent Training N/A
Recruiting NCT04504890 - Ocular-vestibular Biomarker Identification for ADHD
Recruiting NCT06299189 - A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care N/A
Recruiting NCT04729439 - Technology-Enhanced Executive Functioning Intervention for ADHD Phase 1
Completed NCT01685281 - Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder Phase 2